Research Areas
► economics of regulatory institutions, with a focus on good governance (conflicts of interest, revolving door, expert advisory committees, transparency)
► Food and Drug Administration (FDA)
► technologies (prescription drugs, devices, cybersecurity)
Metholodogical Approach
► guided by economic and sociological theory
► quantitative (statistical / econometric) methods
► large administrative, survey, and other datasets
Recent Activity
>> New Publication <<
September 2026
Prediction markets in clinical trials and drug approval. JAMA Health Forum 2026; 7:e262953.
>> Jordi Llinares Lecture at the European Medicines Agency <<
April 2026
Industry influence and the revolving door in drug approval
>> New Working Paper<<
April 2026
Profit regulation and strategic transfer pricing by vertically integrated firms: Evidence from health care. NBER Working Paper 35043.
Medscape
July 30, 2026
Manufacturers report $2.6 billion in Open Payments to physicians, but product details remain murky [PDF]
by Steph Weber
Houston Chronicle
June 22, 2026
Empower Pharmacy’s CEO helped a Houston doctor pay his rent. Is it a conflict of interest? [PDF]
by Julian Gill